"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Descriptor ID |
D000914
|
MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2021 | 2 | 4 | 6 |
2022 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Association Between Maternal Breastmilk Microbiota Composition and Rotavirus Vaccine Response in African, Asian, and European Infants: A Prospective Cohort Study. J Infect Dis. 2023 08 31; 228(5):637-645.
-
The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFa blockade. J Med Virol. 2022 Dec; 94(12):5780-5789.
-
The pre-exposure SARS-CoV-2-specific T?cell repertoire determines the quality of the immune response to vaccination. Immunity. 2022 10 11; 55(10):1924-1939.e5.
-
Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants. Nat Commun. 2021 12 15; 12(1):7288.
-
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open. 2021 12; 7(3).
-
High rate of clinically unrecognized SARS-CoV-2 infections in pediatric palliative care patients. Eur J Pediatr. 2022 Feb; 181(2):847-851.
-
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45?years of age compared to women 16-26?years of age: An open-label phase 3 study. Vaccine. 2021 05 12; 39(20):2800-2809.
-
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. mSphere. 2021 02 24; 6(1).
-
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021 02 12; 371(6530).